Elevation Oncology Boeing Bond
ELEV Stock | USD 0.62 0.01 1.59% |
At this time, Elevation Oncology's Short and Long Term Debt Total is fairly stable compared to the past year. Long Term Debt is likely to climb to about 32.8 M in 2024, whereas Long Term Debt Total is likely to drop slightly above 23.5 M in 2024. . Elevation Oncology's financial risk is the risk to Elevation Oncology stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.3382721 | Current Value 0.26 | Quarterly Volatility 0.01553248 |
Elevation |
Given the importance of Elevation Oncology's capital structure, the first step in the capital decision process is for the management of Elevation Oncology to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Elevation Oncology to issue bonds at a reasonable cost.
Popular Name | Elevation Oncology Boeing Co 2196 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US28623U1016 |
Bond Issue ISIN Code | US097023DG73 |
Elevation Oncology Outstanding Bond Obligations
ELV 49 08 FEB 26 | US28622HAA95 | Details | |
ELV 475 15 FEB 33 | US28622HAB78 | Details | |
ELV 5125 15 FEB 53 | US28622HAC51 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details |
Understaning Elevation Oncology Use of Financial Leverage
Understanding the structure of Elevation Oncology's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Elevation Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | -19.1 M | -20.1 M | |
Short and Long Term Debt Total | 30.1 M | 32.8 M | |
Long Term Debt | 30.1 M | 32.8 M | |
Long Term Debt Total | 26.5 M | 23.5 M | |
Net Debt To EBITDA | 0.46 | 0.44 | |
Debt To Equity | 0.55 | 0.64 | |
Interest Debt Per Share | 1.01 | 1.26 | |
Debt To Assets | 0.34 | 0.26 | |
Long Term Debt To Capitalization | 0.35 | 0.40 | |
Total Debt To Capitalization | 0.35 | 0.40 | |
Debt Equity Ratio | 0.55 | 0.64 | |
Debt Ratio | 0.34 | 0.26 | |
Cash Flow To Debt Ratio | (1.86) | (1.96) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.